We Are Not Yet in Bizarro World

Unclear Reasoning for the Inovio Selloff
Though Inovio (INO) announced positive interim clinical data of INO-4800 (its vaccine candidate against novel coronavirus (SARS-CoV-2)) from the first of two Phase 1 clinical trial cohorts, the stock still fell around 11%.

The reason for the selloff is still unclear to us. Some have said the reason for the stock . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.